Taiho Oncology, Inc.
Sandra Smiljkovic is a seasoned professional in clinical operations and quality assurance, currently serving as Sr. Manager of Quality Assurance at Taiho Oncology, Inc. since April 2023. With prior experience at Gilead Sciences as a Sr. Clinical Trial Management Associate, Sandra demonstrated expertise in monitoring CRO performance, managing vendor activities, and ensuring regulatory compliance for clinical studies. Sandra also contributed to study startup and regulatory processes at Bristol Myers Squibb, where responsibilities included regulatory document submissions and site activation compliance. Earlier in the career, Sandra held a role at ICON plc as a Project Assistant in Medical Imaging, supporting project development and communication. Sandra holds a Bachelor's Degree in Health Services from Philadelphia University and an Associate's Degree from the Community College of Philadelphia.
This person is not in any teams
This person is not in any offices
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com